Compare OMH & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 28.9M |
| IPO Year | 2022 | 2000 |
| Metric | OMH | LSTA |
|---|---|---|
| Price | $0.80 | $3.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 17.4K | ★ 31.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.59 | $1.81 |
| 52 Week High | $3.25 | $5.07 |
| Indicator | OMH | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 40.29 |
| Support Level | $0.75 | $3.02 |
| Resistance Level | $1.38 | $3.41 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 11.72 | 46.64 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.